Previous 10 | Next 10 |
NORTHAMPTON, MA / ACCESSWIRE / February 29, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black...
- 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead's Setting the P.A.C.E. Initiative - FOSTER CITY, CA / ACCESSWIRE / February 28, 2024 / Gilead Sciences, Inc. (NASDAQ:GILD) announced it is providing a total of $12.6 million in grant funding to 19 organi...
– 19 Organizations Will Receive a Total of $12.6 Million in Grant Funding Through Gilead’s Setting the P.A.C.E. Initiative – Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $12.6 million in grant funding to 19 organizations working ...
2024-02-26 17:03:21 ET In 2023, Gilead's total revenues decreased by 1% due to lower Veklury sales, offset by higher HIV and Oncology sales. Net income rose to $5.7 billion, with diluted earnings per share at $4.50. Management focuses on leadership development and mitigating cybersecurity ris...
-- Biktarvy Now First and Only INSTI-Based Single-Tablet Regimen That is FDA Approved and DHHS Guideline Recommended for People Who are Virologically Suppressed with M184V/I Resistance -- -- M184V/I One of the Most Common Forms of Resistance Among People with HIV -- -- Bik...
- Key Findings from HIV Treatment Research Studies Evaluating Biktarvy ® and Investigational Long-Acting Combination Regimens Affirm Commitment to Continuous Biomedical Innovation – – Latest Real-World Evidence Analyses Evaluate Impact of Veklury ® ...
NORTHAMPTON, MA / ACCESSWIRE / February 26, 2024 / This year's theme for National Black HIV/AIDS Awareness Day is "Engage, Educate, Empower: Uniting to End HIV/AIDS in Black Communities." We spoke with C. Virginia Fields, President and CEO of National Black Leadership Commission on Health (Black...
2024-02-25 05:00:00 ET Summary AlphaGen Therapeutics and ArtBio, two targeted RLT companies, forged a far-reaching agreement to expand ArtBio’s market and develop new RLTs. Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences, granting acces...
2024-02-24 07:04:00 ET There are well over 5,000 stocks on the market that pay dividends. It would take you years to analyze each one of them in detail. Fortunately, you don't have to exert such an effort. Three Fool.com contributors have identified dividend stocks that they think are n...
2024-02-24 05:52:00 ET One good year leads to another. That's typically been the pattern for the Nasdaq Composite index since its creation in 1971. The positive years for the index outnumber the negative years by nearly 3 to 1. History is on the side of investors hoping for the Nasd...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...